Pharmalot… Pharmalittle… The Weekend Nears
Make a commentBy Ed Silverman // August 5th, 2011 // 7:08 am
And so, another working week is about to come to an end. Not a moment too soon, yes? This is, of course, our signal to daydream about weekend plans. Our modest agenda includes golfing with our shortest of short people, catching up on some reading and taking at least one cozy nap. And you? How about a day at the beach? A night out with someone special? Or perhaps a shopping trip to stimulate what is left of the economy? Whatever you do, be safe and enjoy. Meanwhile, here is an assortment of tidbits. See you soon…
Pharma Collaborations Are On The Rise (Nature Reviews Drug Discovery)
Payers Will Want More Biosimilar Data Than FDA (Pharma Times)
Cost Of Medicare Part D Drug Plan Is Dropping (The Los Angeles Times)
Takeda And Amylin Pull The Plug On Obesity Drug (Bloomberg News)
NICE Rejection Of Novartis MS Pill Angers Patients (Pharma Times)
Boehringer Gets EU OK For Pradaxa Bloodthinner (Reuters)
PETA Loses Lawsuit Over Merck Shareholder Proposal (Legal Times)
How Novartis Hopes To Cope With Diovan Patent Expiration (Bloomberg News)
Roche Sells Colorado Manufacturing Facility (Boulder County Business Report)
Sri Lanka Assures Better Access To Indian Pharma Exporters (PharmaBiz)
EDITOR’S NOTE: Please check this post for updates throughout the morning.
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Amylin Pharmaceuticals, Biosimilars, Bloodthinner, Boehringer Ingelheim, Colorado, Diovan, FDA, Gilenya, India, Medicare Part D, Merck, MS, Multiple Sclerosis, NICE, Novartis, Obesity, Patent Expirations, PETA, Pradaxa, Roche, Sri Lanka, Takeda Pharmaceuticals, Third-Party Payers, UK